Undisclosed Clinical Program(s)

About Transcripta Bio

Transcripta Bio is an AI-driven drug discovery company founded in 2018 that has developed a first-of-its-kind integrated platform combining high-resolution transcriptomic screening with frontier AI models. The company systematically screens diverse small molecules to build a perturbation atlas, which powers its 'Conductor AI' to predict gene responses and design novel drug candidates for synthesis and validation in its wet lab. This closed-loop system is designed to identify and advance therapeutic programs with unprecedented speed and scale, a capability recognized by its inclusion in the TIME100 Most Influential Companies of 2024. Transcripta Bio operates as a private, likely pre-revenue company advancing a pipeline from discovery through clinical stages.

Therapeutic Areas

Other Not Specified Drugs